Rapid sepsis test Xpert® Xpress GBS

for sexually transmitted diseasesStreptococcus Blaboratory

Group B Streptococcus (GBS) remains a leading cause of early-onset neonatal sepsis. Rates of maternal colonisation have not changed, but universal antenatal screening at 35–37 weeks along with the use of intrapartum antibiotic prophylaxis (IAP) has resulted in a decrease of early-onset disease.1 Challenges remain, including: Risk of change of GBS colonization status following screening at 35–37 weeks of gestation2,3 Some women with unknown GBS status presenting at Labor & Delivery units4,5 Risk-based IAP exposes 65–85% of GBS-negative women to antibiotics6 The Solution Cepheid's Xpert® GBS test is the only in vitro diagnostic test to fully meet CDC criteria for rapid intrapartum GBS testing. On-demand molecular testing — an ideal solution: Dual targets in highly conserved regions for an extended GBS strain coverage Test designed with Early Assay Termination (EAT) to provide positive results in approximately 30 mins Easy-to-use testing with 1 min hands-on time Intrapartum rectal/vaginal swabs can be tested by trained lab, or labor and delivery staff Sample Adequacy Control integration to ensure correct sample incorporation into the cartridge Random access enables any test in the menu to be run at any time, without the need to batch The Impact The Xpert Xpress GBS test can easily be run in near-patient settings by trained non-laboratory personnel. Now clinicians are able to identify GBS colonisation status when it matters most.